IP Library › Granted Patent US 12686866
Granted Patent B2
US 12686866 · App. 17/312,362 · Granted Jul 21, 2026

Methods of treating cancer by suppression of FAMIN expression

Inventors: Arthur Kaser (Cambridge, GB); Mohammed Zaeem Cader (Cambridge, GB)
Assignee: CAMBRIDGE ENTERPRISE LIMITED
C12N15/113A61K31/52A61K31/708A61K35/17A61K38/465A61K40/11A61K40/42A61K40/46A61K45/06A61K2239/31A61K2239/38C12N2310/11C12N2310/14C12N2310/20C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12686866
App. No.
17/312,362
Granted
Jul 21, 2026
Kind
B2
Abstract

This invention relates to the finding that inhibition or inactivation of FAMIN (‘fatty acid metabolism—immunity nexus’; C13orf31: LACC1 (laccase domain containing 1)) reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer orstimulating cell-mediated immune responsesin an individual by reducing FAMIN activity in the individual are provided. Also provided are methodsofactivating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering(a) a population of FAMIN deficient immune cells; or(b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.

Claims (10)

1 . A method of decreasing the proliferation of tumour cells comprising;

contacting the cells with a suppressor nucleic acid or targeted nuclease that reduces expression of active FAMIN polypeptide, wherein the active FAMIN polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 1 over the whole length of SEQ ID NO: 1,

wherein the suppressor nucleic acid comprises a contiguous sequence of 15 to 40 nucleotides of a nucleotide sequence at least 95% identical to SEQ ID NO: 2 or its complement.

2 . The method according to claim 1 wherein the suppressor nucleic acid is a siRNA or shRNA.

3 . The method according to claim 1 wherein the suppressor nucleic acid is an antisense oligonucleotide.

4 . The method of claim 1 wherein the active FAMIN polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

5 . The method of claim 1 wherein the suppressor nucleic acid comprises a contiguous sequence of 15 to 40 nucleotides of SEQ ID NO: 2 or its complement.

6 . The method according to claim 1 wherein the suppressor nucleic acid is administered in combination with an additional therapeutic agent.

7 . The method according to claim 6 wherein the additional therapeutic agent is an immune checkpoint inhibitor.

8 . The method according to claim 6 wherein the additional therapeutic agent is an anti-cancer agent.